您当前的位置：

TM-25659

目录号: PL08411 纯度: ≥99%

TM-25659是具有PDZ结合基序的转录共激活子 (TAZ) 的调制剂。抗骨质疏松和抗肥胖活性。

CAS No. :260553-97-7

商品编号	规格	价格	会员价
PL08411-5mg	5mg	¥769.00	请登录
PL08411-10mg	10mg	¥1175.00	请登录
PL08411-25mg	25mg	¥1975.00	请登录
PL08411-50mg	50mg	询价	询价
PL08411-100mg	100mg	询价	询价
PL08411-200mg	200mg	询价	询价
PL08411-10mM*1mLinDMSO	10mM*1mLinDMSO	¥2828.00	请登录
PL08411-1 mL x 10 mM (in DMSO)		¥853.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

*注意事项:下单时请联系销售核实产品价格及货期，避免后续产生不便，感谢支持!

加入购物车在线咨询收藏产品大包装询价

中文名称	TM-25659
英文名称	TM-25659
英文别名	AK00897912;2-Butyl-5-methyl-6-pyridin-3-yl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridi;TM-25659
Cas No.	260553-97-7
分子式	C₃₀H₂₈N₈
分子量	500.60
包装储存	Powder -20°C 3 years；4°C 2 years
详情描述	TM-25659是具有PDZ结合基序的转录共激活子 (TAZ) 的调制剂。抗骨质疏松和抗肥胖活性。

产品详情	TM-25659是具有PDZ结合基序的转录共激活子 (TAZ) 的调制剂。抗骨质疏松和抗肥胖活性。
生物活性	TM-25659 is a transcriptional co-activator with PDZ-binding motif (TAZ) modulator. Anti-osteoporotic and anti-obesity activities.
性状	Solid
IC50 & Target[1][2]	TAZ
体外研究(In Vitro)	TM-25659 (2, 10, 20, 100 μM) enhances nuclear TAZ localization in a dose-dependent manner and attenuates PPARγ-mediated adipocyte differentiation by facilitating PPARγ suppression activity of TAZ.TM-25659 (2, 10, 50 μM) enhances osteogenic gene expression and thereby increases osteoblast differentiation. has not independently confirmed the accuracy of these methods. They are for reference only.Cell Proliferation Assay
体内研究(In Vivo)	TM-25659 (50 mg/kg, i.p., every other day for 2 weeks) suppresses bone loss in vivo and decreases weight gain in an obesity model. TM-25659 has a favourable pharmacokinetic profile in rats. The plasma concentration of TM-25659 declines with an approximate t 1/2 of 7 or 10 h following i.v or p.o. administration respectively. The systemic clearance (CL) is 0.21 L×h×kg and the volume of distribution at steady-state (1.91 L×h×kg) is larger than the volume of total body fluids. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Jang EJ, et al. TM-25659 enhances osteogenic differentiation and suppresses adipogenic differentiation by modulating the transcriptional co-activator TAZ. Br J Pharmacol. 2012 Mar;165(5):1584-94.

溶解度数据	In Vitro: DMSO : ≥ 135 mg/mL (269.68 mM)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

[1]. Jang EJ, et al. TM-25659 enhances osteogenic differentiation and suppresses adipogenic differentiation by modulating the transcriptional co-activator TAZ. Br J Pharmacol. 2012 Mar;165(5):1584-94.

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

TM-25659

相关产品

The molarity calculator equation

The dilution calculator equation